Full Press Release Details
Accessibility: Skip TopNav
DBV Technologies to Attend Upcoming Investor Conferences
June 02, 2015 01:30 ET
DBV Technologies S.A.
DBV Technologies S.A.
DBV Technologies to Attend Upcoming Investor Conferences
DBV Technologies, (Euronext: DBV - ISIN: FR0010417345 - Nasdaq Stock Market: DBVT), a clinical-stage specialty biopharmaceutical company, today announced that Susanna Mesa, Vice President Finance, Investor Relations & Strategy, will present and host investor meetings at the following upcoming investor conferences:
Jefferies 2015 Health Care Conference at the Grand Hyatt, New York, NY, on June 1-4, 2015.
Goldman Sachs 36th Annual Global Healthcare Conference at the Terranea Resort, Ranchos Palos Verdes, CA, on June 9-11.
A live audio webcast of the Jefferies' presentation will be available on the Investor Relations section of the Company's website, http://www.dbv-technologies.com/en/investor-relations. A replay of the presentation will also be available on DBV's website within 48 hours after the event.
About DBV Technologies
DBV Technologies is developing Viaskin®, an innovative new approach to the treatment of allergies - a major public health issue that has been increasing in prevalence. DBV Technologies, incorporated in France in 2002, has developed a proprietary, patented technology for administering an allergen to intact skin while avoiding transfer to the blood, and thus lowering the risk of a systemic, allergic reaction in the event of accidental exposure. DBV Technologies is focusing on food allergies, including milk and peanut, for which there are currently no effective treatments. DBV Technologies has designed two products candidates: Viaskin® Peanut and Viaskin® Milk. The clinical development program for Viaskin® Peanut has received Fast Track designation and Breakthrough Therapy designation from the U.S. Food and Drug Administration.
DBV Technologies shares are traded on segment B of Euronext Paris (Ticker: DBV, ISIN code: FR0010417345) and on the Nasdaq Stock Market in the form of American Depositary Shares (each representing one-half of one ordinary share) (Ticker: DBVT). For more information on DBV Technologies, please visit our website: www.dbv-technologies.com
| DBV Technologies Contacts | |
| Nathalie Donne Director, Corporate Communication & Business Development Tél. : +33(0)1 55 42 78 72 nathalie.donne@dbv-technologies.com | Susanna Mesa VP Finance, US Investor Relations & Strategy Tél. : +1 917-346-3447 susanna.mesa@dbv-technologies.com |
| DBV Technologies Media Contacts | |
| Marion Janic Rooney & Associates Tél. : +1-212-223-4017 mjanic@rooneyco.com |